

Interleukin-25-mediated resistance against intestinal trematodes does not depend on the generation of Th2 responses

Maria Álvarez-Izquierdo
Universitat de Valencia

Miguel Pérez-Crespo
Universitat de Valencia

J. Guillermo Esteban
Universitat de Valencia

Carla Muñoz-Antoli
Universitat de Valencia

Rafael Toledo (✉ rafael.toledo@uv.es)
Universitat de València <https://orcid.org/0000-0003-2651-9794>

Research

Keywords: Interleukin-25, Echinostoma caproni, caproni

Posted Date: October 28th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-41238/v2>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on December 4th, 2020. See the published version at <https://doi.org/10.1186/s13071-020-04467-7>.

Abstract

Background: Interleukin-25 (IL-25) is recognized as the most relevant initiator of protective Th2 responses in intestinal helminth infections. It is well known that IL-25 induces resistance against several species of intestinal helminths, including the trematode *Echinostoma caproni*. *Echinostoma caproni* has been extensively used as an experimental model to study the factors determining the resistance to intestinal infections. Herein, we assessed the role of IL-25 in the generation of resistance in mice to *E. caproni* infections.

Methods: To this purpose, we analyze the factors that determine the production of IL-25 in mice experimentally infected with *E. caproni* and its consequences in the polarization of the immune response and the resistance to infection.

Results: We have determined that the role of IL-25 in the polarization of the immune response differs between the primary and secondary response. IL-25 is required for the development of a Th2 phenotype in primary *E. caproni* infections but could also promote the differentiation to Th2 memory cell subsets that enhances type 2 responses in memory responses. However, development of Th2 responses does not induce resistance to infection. Th2 phenotype does not elicit resistance and IL-25 is responsible for the resistance regardless of the type 2 cytokine activity and STAT6 activation. Alternative activation of macrophages induced by IL-25 could be implicated in the resistance to infection.

Conclusions: In contrast to primary infection, secondary infection elicits a type 2 response, even in the absence of IL-25 expression. Despite the development of a type 2 response, mice are susceptible to secondary infection in relation to the lack of IL-25. Resistance to infection is due to IL-25, which acts autonomously from Th2 response in the parasite clearance.

Background

Intestinal helminth infections are common in man and animals, especially in developing regions of Africa, Asia and the Americas [1-3]. These parasitic infections generate substantial morbidity and produce relevant physical and mental disorders and often persist in the face of serious economic problems [2]. Moreover, infections by intestinal helminths also compromise the health and productivity of livestock worldwide [3]. Currently, the impact of intestinal helminth infections mainly can be reduced by anthelmintic treatment, but the progressive emergence of resistances to these drugs limits their utility. Furthermore, the fact that infections do not generate protective immunity causes continuous reinfections in environments of poverty and deficient sanitary conditions. Despite these facts, no available effective vaccines to protect humans or animals exist. Among other factors, the lack of knowledge on how protective immunity is selected after infection is a major obstacle to successful immunization [4].

Resistance to intestinal helminths is based on the generation of Th2 responses in a complex process that involves the interaction between innate and adaptive mechanisms [5-7]. Protective Th2 immunity against intestinal helminths is initiated and amplified by the epithelial-derived alarmin cytokines including

IL-25, IL-33 and thymic stromal lymphopoietin (TSLP), though the immune mechanisms behind the development of these responses are poorly understood [6,8]. In recent years, IL-25, a member of the IL-17 family of cytokines also called IL-17E, has been considered a key cytokine since it promotes Th2 immunity and exerts anti-inflammatory functions via the downregulation of Th17 and Th1 responses [9-12]. IL-25 expression is generally associated with resistance to gastrointestinal helminth infections through the activation of Th2 responses that mediate effector mechanisms for parasite expulsion (which include goblet cell hyperplasia, smooth muscle hypercontractility, expression of resistin-like molecule-beta (RELM-b), and intestinal mastocytosis, amongst others) [6]. Recent work has uncovered the origin and the mechanisms of action of IL-25 [13-15]. Despite these, there are several doubts in relation to the role of IL-25 in the generation of protective Th2 responses to intestinal helminth infections [8,16-17]. For example, it is not well defined if the participation of IL-25 is limited to its ability to promote Th2 responses or if it is directly involved in the activation of effector mechanisms responsible for resistance. Likewise, its potential role in the differentiation of Th cells to memory subset cells and their implications in the generation of immunity against intestinal helminths is unknown. Several recent studies have questioned the role of IL-25 on the generation of adaptive type 2 responses or the differentiation of Th2 cells or their development to effector or memory Th2-cell subsets [8,16].

Apart from their interest as human parasites mainly in East and Southeast Asia [18-19] echinostomes, and particularly *Echinostoma caproni* (Trematoda: Echinostomatidae), have been extensively used for the establishment of chronic infections or the development of resistance to intestinal helminths.

Echinostoma caproni is an intestinal trematode with no tissue phase in the vertebrate definitive host [20]. After infection, the metacercariae excyst in the duodenum and the juvenile worms migrate to the ileum, where they attach to the mucosa. *E. caproni* has a wide range of definitive hosts, although its compatibility differs considerably between rodent species in terms of worm survival and development [21]. In mice and other hosts of high compatibility, the infection becomes chronic, while in hosts of low compatibility, (e.g. rats) the worms are expelled from the 2-4 weeks post-infection [22-23]. The establishment of chronic infections in ICR mice is dependent upon a local Th1 response with elevated production of IFN-g [24]. In contrast, the resistance to *E. caproni* infection in hosts of low compatibility is associated with the development of a local Th2 phenotype [24-25]. Because of these characteristics, the *E. caproni*-rodent model is useful to elucidate several aspects of the host-parasite relationships in intestinal infections, such as the induction of distinct effector mechanisms and their effectiveness in parasite clearance. Recent studies of our group showed that partial resistance against *E. caproni* secondary infections in ICR mice is developed after chemotherapeutic cure of a primary infection and innately produced IL-25 is crucial to determine the resistance. Susceptibility to primary infections was associated with low levels of intestinal IL-25 gene expression, whilst deworming via administration of praziquantel (pzq) was accompanied by a steady increase in IL-25 expression and, in turn, by the onset of a Th2-type response that prevented the establishment of secondary infections [26-27].

In the present work, we investigate the role of IL-25 in resistance to *E. caproni* infections in mice. Our results show that IL-25, but not type 2 response, is required for resistance. However, IL-25 could have a role in the differentiation of Th2 memory subset, facilitating Th2 responses to challenge infections.

Susceptibility of mice to *E. caproni* infections relies on the fact that parasite compounds do not elicit IL-25 responses in mice and the upregulation of this cytokine depends on external factors.

Material And Methods

Parasites, hosts and experimental primary and secondary infections

Encysted metacercariae of *E. caproni* were removed from the kidney and pericardial cavity of experimentally infected *Biomphalaria glabrata* snails and used to infect male ICR mice weighing 30-35 g by gastric gavage both primary and challenge infections (50 metacercariae each). Positivity of infection in each case was determined at necropsy or detection of eggs in stools [22]. Animals were maintained under conventional conditions with food and water ad libitum. Each experiment was performed in triplicate.

Ethical statement

This study has been approved by the Ethical Committee of Animal Welfare and Experimentation of the University of Valencia (Ref#A18348501775). Protocols adhered to Spanish (Real Decreto 53/2013) and European (2010/63/UE) regulations.

Pharmacological treatment of primary infections

Cure of the primary infections was achieved by pharmacological treatment with pzq. Mice were treated with a double dose of 100 mg/Kg of pzq at 4 weeks post-primary infection (wppi), orally administered on alternate days [28]. All mice treated with pzq reverted to negative as determined by coprological examination. The influence of the pharmacological treatment over the studied parameters was discarded since five mice were left uninfected, treated with pzq as described above and analyzed.

Treatment of mice with blocking antibodies or isotype-matched IgG control antibodies

Briefly, several mice were sensitized by intraperitoneal injection with commercial specific blocking antibodies, recombinant proteins or isotype matched control antibodies.

To neutralize the effect of IL-25 produced nonspecifically after the curation of the primary *E. caproni* infection and to investigate the effect of this cytokine in a secondary challenge infection and the role of STAT6 activation in resistance to infection, two groups of 5 mice each were treated with monoclonal anti-mouse IL-25 (ma-IL-25) (R&D Systems) or monoclonal anti-mouse IL-4Ra (ma-IL-4Ra) (Biolegend). In each group, mice were primarily infected with 50 metacercariae of *E. caproni* and treated with pzq at 4 wppi. On each of the two days previous to a secondary infection at 6 wppi, mice were intraperitoneally injected with either ma-IL-25 (concentration: 0.25 mg/ml) in one of the groups or ma-IL-4Ra (concentration: 0.1 mg/ml) to the mice belonging to the other group in 150 ml of saline buffer. Additionally, and to be used as control of the ma-IL-25-treated mice, 5 mice were injected with rat IgG1

and other 5 mice with IgG2b and used as controls for the ma-IL-4Ra-treated group of animals. All mice were sacrificed at 2 weeks post-secondary infection (wpsi).

Recombinant cytokines were used to analyze their effect on the course of the infection. For this purpose, groups of 5 mice were intraperitoneally injected with either IL-4 (rIL-4; Preprotech), IL-13 (rIL-13; Preprotech) or IL-25 (rIL-25; R&D Systems) (concentration: 0.2 mg/ml each) in 150 ml of PBS during each of the 4 days from the primary infection with 50 metacercariae of *E. caproni*. All mice were sacrificed at 2 wpsi. Additionally, a group of five mice were treated with recombinant IL-13Ra2 (rIL-13Ra2; R&D Systems) (concentration: 0.2 mg/ml) following identical protocol to study the role of IL-13Ra2 in *E. caproni* infection. As control animals, five mice were intraperitoneally injected with 150 ml of PBS following the same protocol.

Analysis of IL-25 gene expression over time and its influence in resistance to secondary infections

To analyze further the role of the innately produced IL-25 and the ability of *E. caproni* to induce IL-25 mRNA expression in mice in memory secondary infections, we delayed the challenge infection until IL-25 gene expression recovered to baseline levels. To this purpose, a total of 20 mice were primarily infected with metacercariae of *E. caproni* and treated with pzq at 4 wpi. From 6 wppi, 3 of these mice were sacrificed every two weeks and the levels of IL-25 mRNA expression were studied by rtPCR. Once baseline levels were recovered, the remainder 5 mice of the group were secondarily infected and necropsied at 12 wppt. Moreover, 5 other mice were used as control. To avoid age-related changes in susceptibility allowing accurate comparisons, these mice were aged and primarily infected having the same age than those that were secondarily infected.

Total RNA extraction

Total RNA was extracted from full-thickness sections of ileum of necropsied mice. Total RNA was isolated using Real Total ARN Spin Plus kit (Durviz) according to the manufacturer's instructions. The cDNA was synthesized using High Capacity cDNA Reverse Transcription kit (Applied Biosystems).

Real-Time PCR and relative quantification analysis

For quantitative PCR, 40 ng total RNA was reverse transcribed to cDNA and added to 10 μ L of TaqMan Universal PCR Master Mix, No AmpErase UNG (2x), 1 μ L of the specified TaqMan Gene Expression Assay, and water to a final reaction volume of 20 μ L. Reactions were performed on the Abi Prism 7000 (Applied Biosystems), with the following thermal cycler conditions: initial setup of 10 min at 95 °C, and 40 cycles of 15 s denaturation at 95 °C and 1 min of annealing/extension at 60 °C each. Samples were amplified in a 96-well plate. In each plate, endogenous control, samples and negative controls were analyzed in triplicate. All TaqMan Gene Expression primers and probes for inducible nitric oxide synthase (iNOS), cytokines and mucins were designed by Applied Biosystems and offered as Inventoried Assays. The assay ID details are shown in Additional file 1: Table S1. Each assay contains two unlabeled primers and one 6-FAM dye-labeled, TaqMan MGB probe. Primer concentration was optimized by a matrix of reactions

testing a range of concentrations for each primer against different concentrations of the partner primer and also negative controls were included.

Cycle threshold (Ct) value was calculated for each sample, housekeeping and uninfected control. To normalize for differences in efficiency of sample extraction or cDNA synthesis we used β -actin as housekeeping gene. To estimate the influence of infection in the gene expression levels we used a comparative quantification method ($2^{-\Delta\Delta CT}$ – method). This method is based on the fact that the difference in threshold cycles (ΔCt) between the gene of interest and the housekeeping gene is proportional to the relative expression level of the gene of interest. The fold change in the target gene was normalized to β -actin and standardized to the expression at time 0 (uninfected animals) to generate a relative quantification of the expression levels.

Analysis of goblet cell responses

Goblet cell responses to *E. caproni* infections in the ileum of mice were evaluated in primary and secondary infections in rIL-25-treated mice. At each time point, 5 mice in each group were necropsied and ileal sections of about 0.7 cm in length were obtained and fixed in 4% paraformaldehyde (PFA). After embedding in paraffin wax, serial 4 mm-sections were cut from each tissue block and stained with alcian blue. Cell counts were calculated as the number of goblet cells per crypt unit studied over 10 selected high power field (400x).

Indirect immunofluorescence

Translocation and phosphorylation of STAT6 were study by fluorescent immunohistochemistry on paraffin-embedded tissue sections [29]. Rabbit antibodies anti-STAT6 (ThermoFisher Scientific) and anti-p-STAT6 (ThermoFisher Scientific) were used. Anti-STAT6 and anti-p-STAT6 were diluted 1/200 and 1/20, respectively, in PBS containing 0.3% Triton X-100 and 10% FCS and incubated for 2h in a humid chamber at room temperature, under continuous agitation. After washing 3 times in PBS, intestinal sections were incubated for 2 h with secondary antibody, goat anti-rabbit IgG conjugated with Alexa Fluor® 647 (Jackson ImmunoResearch Laboratories, Inc.), diluted 1/600 in PBS-Triton™ X-100 (0.3%) for Anti-STAT6 and 1/100 for anti-p-STAT6. Slides were washed in PBS and cell nuclei were counterstained with DAPI before mounting with Fluoromoun (Sigma-Aldrich). Cell staining was analyzed by fluorescence microscopy. Results were studied over 5 selected fields.

Enzyme immunohistochemistry

To analyze the tuft cells and GATA3+ cells, such as ILC2 and Th2 populations in primary and secondary infections with *E. caproni*, enzymatic immunohistochemistry of intestinal sections was performed in a total of 20 mice at 2 wppi (n=5), 2 wppt (n=5) and 2 wpsi (n=5). Additionally, 5 naïve mice were used as controls. Initially, intestinal samples of those mice, were dewaxed by incubating them for 20 minutes in an oven at 60 ° C, passed through a hydration chain (Xylene 4x 5 min - 100% Ethanol 2x 3 min - 90% Ethanol 2x 3 min - 70% Ethanol 2x 3min) and were incubated in 10 mM Sodium Citrate Buffer for 10 min

to improve antigen detection. Once the samples were cooled, they were kept in running water for 10 min and washed twice for 5 minutes in Tris Buffer Saline (TBS) + 0.1% Triton X-100 pH 7.6 while stirring. Sections were blocked with 2.5% Normal Goat Serum (Vector) for 1 hour at room temperature. After blocking, they were incubated over night at 4 ° C with the primary antibody at 1: 1000 dilution in TBS and 1% BSA. As primary antibodies were used: a-DCLK-1 (Abcam) for labeling tuft cells and a-GATA3 (Abcam) for labeling GATA3+ cells.

In order to eliminate the own autofluorescence from the tissue, the samples were incubated in Dual Endogenous Enzyme Block (Dako) for 10 min at room temperature. They are then incubated with the secondary Polyclonal Goat anti-Rabbit Immunoglobulins HRP (Dako) antibody diluted 1: 1000 in TBS + 0.1% Triton X-100 and 1% BSA for 1 hour at room temperature. After all incubation steps, 2 washes of 5min were performed with TBS + 0.1% Triton X-100 with gentle agitation.

DAB was selected as a chromogen to reveal the reaction (Liquid DAB + Substrate Chromogen System, Dako). The development time must be controlled by observing the brown precipitates produced by reacting the DAB with the Ab2-HRP. The samples are washed with running tap water to stop the reaction.

Finally, the sections were contrasted with Mayer's Hematoxilin (Dako), passed through a dehydration chain (Scott's tap water 30 sec - 90% Ethanol 2x30sec - 100% Ethanol 2x 3min - Xylene 2x 3 min) and mounted in DPX liquid medium for later analysis in an optical microscope at a magnitude of 200x magnification. Cell populations were studied over 10 selected representative fields.

Statistical analysis

Chi-squared test (χ^2) test was used to compare between both groups of mice at each week post-infection. To compare the worm recovery between primary and challenge infections, a Student's t-test was used at each week post-infection. One-way ANOVA with Bonferroni test, as post-hoc analysis was used to compare gene expression levels of cytokines, enzymes, or other genes analyzed by PCR. $P < 0.05$ was considered as significant. Prior to analyses, data were log transformed to achieve normality and verified by the Anderson–Darling Test.

Results

Treatment of mice with rIL-4 or rIL-13 does not induce resistance to primary infection

The results obtained show that neither treatment with rIL-4 nor rIL-13 induced resistance to primary infection. The worm recovery in rIL-4- [51-65% (61.2 ± 11.2)], rIL-13-treated [62-85% (76.1 ± 16.5)] or non-treated mice [54-68% (62.1 ± 10.6)] was very similar.

Treatment of mice with rIL-4 induced decreases in the expression of IL-13 and IL-12p35. Infection of treated mice elicited a marked downregulation of type 1 cytokines such as IL-12p35, IL-12-p40 or IFN-g. In rIL-4-treated mice, a significant upregulation of IL-13 also was observed (Additional file 2: Figure S1A). No

significant differences between groups were detected in the remainder cytokines or in the expression of markers of macrophage activation (data not shown).

Goblet cell counts in naïve mice ranged from 6.1 to 9.4 cells per crypt (8.1 ± 1.2 cells per crypt). Treatment with rIL-13 induced significant goblet cell hyperplasia (13.1 ± 2.5 cells per crypt) that were more pronounced after infection of the treated mice (19.3 ± 4.3 cells per crypt). In contrast, hyperplasia after the experimental infection only was observed in the animals treated with rIL-4 (15.3 ± 2.9 cells per crypt). RELM-b expression became downregulated in animals treated with rIL-4 but, in contrast, the values were greater than in controls in rIL-13-treated mice at 2 wppi (Additional file 2: Figure S1B).

Secondary *E. caproni* infection induces expansion of tuft cells and GATA3+ cells concomitantly with a Th2 response

Primary infection did not elicit hyperplasia of tuft cells and only a slight increase in GATA3+ cells populations was observed, though rapidly returned to basal values. No increase was observed after treatment with pzq in neither cell type. In contrast, a marked increase in counts of tuft cells and GATA3+ cells was observed as a consequence of the secondary infection (Additional files 3,4: Figures S2 and S3).

Blocking of IL-25 reverts resistance against *E. caproni* challenge infections

To analyze the effect of IL-25 in resistance to *E. caproni* challenge infections, a total of 10 mice were given a primary infection and treated with pzq at 4 wpi. A total of 5 of those mice were treated with ma-IL-25 before a challenge *E. caproni* infection at 2 wppt. The remainder mice were given a secondary infection at the same time without ma-IL-25 treatment. All mice were necropsied at 2 wpsi.

The results obtained show that blockade of the IL-25 reverted the partial resistance to infection and the number of worms recovered was significantly higher in the animals treated with ma-IL-25 than in non-treated mice at necropsy (Fig. 1A). Worm recoveries in ma-IL-25-treated mice ranged from 78-89% (84.00 ± 3.9), whereas the values ranged from 9-32% (23.12 ± 8.2) in non-treated animals.

Changes in cytokine expression in secondary infection at 2 wpsi in relation to the blockade of IL-25 were investigated by real-time PCR. The most relevant alterations affected IL-4, IL-13 and endogenous IL-25. Blockade of IL-25, results in a significant overexpression of IL-4 and IL-13 and a reduction in the expression of endogenous IL-25 (Fig. 1B).

Animals treated with ma-IL-25 showed a similar cytokine profile to non-treated mice. In both groups a type 2 response was generated with elevated gene expression of IL-4 and IL-13 after the challenge infection. Probably, the most striking feature observed was the significantly lower gene expression of endogenous IL-25 in ma-IL-25-treated animals similar to naïve levels (Fig. 1B).

To study the changes in macrophage activation induced by the blockade of IL-25, we have analyzed markers of classical or M1 (Arg II and iNOS) and alternative or M2 (Ym-1 and Arg 1) activation. Interestingly, antibody blockade of endogenous IL-25 did not change the predominance of M2 activation,

despite a slight decrease in Arg1 gene expression was detected. However, a significant decrease in the expression of Arg I, Arg II and iNOS was observed with respect to the group of non-treated mice (Fig. 2A). Moreover, blocking of IL-25 did not induce changes in RELM-b expression (Fig. 2B).

Return to baseline expression of IL-25 after healing of the primary infection ablated the resistance against challenge infection

To analyze further the role of the innately produced IL-25 and the ability of *E. caproni* to induce IL-25 expression in mice in memory secondary infections, we delayed the challenge infection until IL-25 gene expression recovered to baseline levels and compared with other animals of the same age but primarily infected. Baseline levels of IL-25 mRNA in treated mice were recovered at 10 wppt with values statistically similar to naïve controls (Fig. 3).

Results of worm recovery show that after declination of levels of IL-25 mRNA expression, mice were susceptible to infection again. The worm recovery in secondary infections in absence of IL-25 [46-59% (54.2 ± 11.1)] was similar to that of observed in the animals of the same age primarily infected [49-61% (58.6 ± 13.6)] (Fig. 4A).

The profile of cytokine mRNA expression showed that secondary infection at 10 wppt induced the development of a Th2 phenotype, despite the lack of IL-25 at the time of infection (Fig. 4B). Secondary infection at 10 wppt was characterized by significant upregulation of IL-4 and IL-13 and unaltered or downregulation of type 1 cytokines such as, IL-12p35 or IL-12p40 or IFN-g. In contrast, primary infection induced a Th1 response. No differences between groups was observed in relation to endogenous IL-25 expression (Fig. 4B).

Activation of STAT6 is not required for resistance against *E. caproni*

To evaluate the role of STAT6 activation in the resistance mediated by IL-25, we used two experimental approaches in resistant rIL-25-treated mice. In a group of mice, we blocked IL-4Ra using monoclonal antibodies before a primary infection with 50 metacercariae. A second group of mice, was treated with rIL-13Ra2 before the infection. The remaining rIL-25-treated mice were exclusively infected with 50 *E. caproni* metacercariae and were used as control of the effect of treatment with IL-4Ra and/or rIL-13Ra2. All mice were necropsied at 2 wppi.

All the 15 mice were refractory to infection in relation to the treatment with rIL-25. In the two groups of animals, blocked IL-4Ra and rIL-13Ra2-treated mice, a significant reduction in STAT6 phosphorylation and translocation with respect to rIL-25-treated control animals was observed at 2 wppi. In the group of treated with antibodies anti-IL-4Ra, the signal was similar to that observed in naïve animals (Additional file 5: Figure S4).

However, the response generated after exposure to metacercariae was different in each group of mice. A type 1 phenotype was developed with elevated levels of IFN-g gene expression and no significant changes in IL-4 and IL-13 with respect to naïve controls. No significant changes as compared with naïve

mice were observed either in the endogenous expression of IL-25 mRNA or in the other cytokines studied. In contrast, treatment of mice with rIL-13Ra2 abrogated any response to infection and no increase in the expression of any cytokine was observed. A decline in the expression of IL-4 and endogenous IL-25 with respect to naïve mice was observed (Fig. 5A). The expression of the remaining cytokines remained unaltered in this group of mice. Moreover, slight increases in the expression of iNOS and RELM-b were observed in the group of mice treated with anti-IL-4Ra (Fig. 5B).

The expression of IL-13Ra2 in different situations was studied by quantitative PCR. Primary infection resulted in a slight increase in the expression, which increased greatly after pZq-treatment and just before secondary infection associated with resistance. expression declined to negative values after secondary infections (Fig. 6).

Discussion

Primary infection of mice with *E. caproni* does not elicit IL-25 upregulation. However, pharmacological cure of the primary infection induced a marked overexpression of IL-25. Due to these elevated levels of IL-25 gene expression, mice became resistant to a challenge infection at 2 wppt, concomitantly with the development of a robust Th2 response [26-27]. Extending our previous studies, the present work was designed to analyze the role of IL-25 in the generation resistance to *E. caproni* infections in mice. The study has been focused on the factors determining IL-25 upregulation, the immune regulatory role of IL-25 and the effector mechanisms induced by IL-25 that determine resistance.

Although it is generally accepted that IL-25 is critical for resistance against intestinal helminths, there is not consensus in relation to the mechanisms by which this cytokine enhances resistance. Traditionally, the role of IL-25 in resistance has been exclusively attributed to its immune regulatory activity. IL-25 promotes Th2 immunity with production of IL-4 and/or IL-13 which, in turn, induce STAT6-mediated intestinal alterations determining parasite rejection [9,30-33]. Upon helminth establishment, intestinal tuft cell populations expand and release IL-25 that activate a variety of immune cells to initiate type 2 responses and promote Th2-cell-mediated immunity. In response to IL-25 and other alarmins, ILC2 produce large amounts of IL-13 that polarize naïve CD4+ T cells into Th2. Antigen-presenting cells, such as basophils and dendritic cells, are also activated and induce Th2 polarization through different mechanisms [6,13,15]. This is consistent with our results, since we observed that in resistant secondary infections against *E. caproni* there were an expansion of the populations of tuft cells and GATA3+ cells. The effector mechanisms activated in the resistance response against *E. caproni* seem to be dependent on the expansion of the tuft cells, thereby promoting the overexpression of IL-25 and activation of ILC2 or Th2 cells. In an environment of helminth infection, IL-25 acts as a mediator of the activation of ILC2s promoting the polarization of the immune response towards a Th2 phenotype [34].

A number of laboratories have reported that IL-25 upregulation is induced by the infection with intestinal helminths such as *Nippostrongylus brasiliensis*, *Trichinella spiralis*, *Trichuris muris* or *Heligmosomoides polygyrus* leading to activation of type 2 responses and resistance to infection [9,30-33,35]. Despite these

studies, recent works have suggested that the regulatory role of IL-25 may be secondary and this cytokine operates autonomously from Th2 response in the generation of resistance against intestinal helminths [8,16]. Smith and co-workers [8] showed that IL-25 plays a more important role than simply the promotion of protective Th2 responses. In fact, these authors demonstrated that adaptive Th2 response to *H. polygyrus* in mice developed normally even in the absence of IL-25R activation, but effector mechanisms became impaired. Similarly, Mearns et al. [16] challenged the role of IL-25 in the promotion of Th2 responses in intestinal helminth infections. Using crossed IL-25^{-/-} C57BL/6 mice and 64 IL-4 C57BL/6 reporter mice, these authors demonstrated no physiological role for IL-25 for either the differentiation of Th2 cells or their development to effector or memory Th2-cell subsets. For instance, IL-25 deficient mice mounted normal Th2 responses following *N. brasiliensis* infections. Our results, indicate that involvement of IL-25 in intestinal helminth infections may be more complex than previously expected. IL-25 is required for resistance against *E. caproni* infection in mice, but this resistance is independent of IL-4 and/or IL-13 activity and STAT6 activation. Furthermore, IL-25 may have a role in promoting Th2 responses though its contribution is different in primary and memory secondary responses. IL-25 is required for the development of a Th2 phenotype in response to primary infections but, in contrast, memory response is characterized by the upregulation of type 2 cytokines despite the lack of IL-25, suggesting that IL-25 enhances the expansion memory cells.

The inability of mice to produce IL-25 in response to primary infection and, consequently IL-13, results in susceptibility to infection. However, treatment of mice with rIL-25 induced resistance to infection, concomitantly with elevated levels of IL-13 [26]. Our results confirm that the development of a Th2 response relies on the presence of IL-13 and STAT6 activation. Despite the lack of IL-25, treatment of mice with rIL-4 or rIL-13 elicited a Th2 phenotype in response to *E. caproni* primary infection and the activation of several IL-13-mediated mechanisms such as goblet cell hyperplasia or RELM-b activation. Our results also support that STAT6 activation is required for the production of type 2 cytokines in response to *E. caproni* primary infection. Blocking of IL-4Ra in mice treated with rIL-25 induced a decline in STAT6 phosphorylation and a Th1 response to infection. Furthermore, our results suggest that IL-13Ra2 plays an important role in the regulation of the response to primary infection. Treatment of mice with IL-13Ra2 abrogated the immune response to *E. caproni* primary infection despite the presence of rIL-25.

IL-4 and IL-13 share a common receptor, the IL-4Ra chain, but IL-13 also uses IL-13Ra1 for signaling via JAK1 and JAK2. IL-13 binds 13Ra1 which complexes with IL-4Ra to form the type 1 receptor signaling, but IL-13 also binds the cell surface and soluble forms of the monomeric type 2 receptor (IL-13Ra2 chain). However, IL-13Ra2 has a decoy effect, lacking signal transduction machinery and limiting the activity of IL-13 since binds the cytokine making it unavailable for activating type 1 receptor [36-39]. Herein, we have shown that rIL-13Ra2 chain limits the ability of mice to respond to *E. caproni* primary infection, even in the presence of rIL-25. Treatment of mice with both rIL-25 and rIL-13Ra2 abrogated the response to *E. caproni* infection and no changes in cytokine gene expression were observed as a consequence of the infection. IL-13Ra2 may act as negative regulator of both IL-13 inhibiting signal

transduction and STAT6 activation by the preferential binding of IL-13 to IL-13Ra2 [40]. However, IL-13Ra2 also inhibits IL-4 induced STAT6 activation and interact with IL-4Ra, even in the absence of IL-13. IL-13Ra2 probably blocks the activation of STAT6 by the physical interaction between the short domain of with the cytoplasmic domain of the IL-4Ra chain that harbors the STAT6 docking sites [36,39-40]. In fact, we have observed that IL-13Ra2 expression is importantly upregulated coinciding with the resistance to secondary infection at 2 wppt.

In contrast to which occurs in primary infections, IL-25 does not appear to be required for the development of Th2 responses in secondary *E. caproni* infections. Herein, we have shown that mice also are unable to produce IL-25 in a secondary challenge infection. Despite this fact, secondary *E. caproni* infection at 2 wppt induced a Th2 response. This was attributed to the presence of elevated levels of IL-25 produced after the cure of the primary infection [26]. However, blocking of the IL-25 innately produced after healing of the primary infection gave rise to a type 2 response as a consequence of the secondary infection showing that IL-25 was not related to the biasing of the immune response. This is in contrast with the results obtained with other intestinal helminths. In *H. polygyrus* infections, both primary and secondary infections included IL-25, but both responses were different. IL-25 response in secondary infections was higher, concomitantly with a more potent Th2 response and enhanced resistance to infection. In contrast, the lower levels of IL-25 overexpression to primary infections, was reflected in a weak response of Th2 cytokines and chronic infections [35]. Although IL-25 does not appear to determine the polarization of Th2 cells in secondary *E. caproni* infections, this cytokine could facilitate the development to memory Th2 cell subsets. Mearns and co-workers [16] reported that there was not requirement for IL-25 in the development of Th2 cells during *H. polygyrus* infections. To analyze the role of IL-25 in the generation of memory responses against resistance to *E. caproni*, we delayed the challenge infection until the levels of innate IL-25 gene expression upregulation declined to baseline, which occurred at 10 wppt. Mice were susceptible to the challenge infection despite the development of a Th2 phenotype with elevated levels of IL-4 and IL-13 gene expression but low levels of endogenous expression of IL-25. This suggest that innately produced IL-25 after healing of a primary infection is involved in the differentiation of memory cells.

Resistance to *E. caproni* primary infection was associated with IL-4-independent mechanisms and based on IL-13 activity and STAT6 activation [24-25]. However, recent studies have suggested that mechanisms of resistance to intestinal helminth infections mediated by IL-25 are not dependent on IL-4 and/or IL-13 activity [8]. Our results support the notion that IL-25 operates autonomously from type 2 cytokines and the generation of resistance is exclusively mediated by IL-25. Treatment of mice with rIL-4 or rIL-13 did not provide of resistance to a primary *E. caproni* infection in relation to the lack of IL-25, despite the development of a Th2 response.

Blocking of the IL-13 receptors induced a significant reduction of STAT6 phosphorylation concomitantly with a reduction of goblet cell hyperplasia and downregulation of RELM-b. However, both control animals and those with the blocked IL-13 receptors were refractory to primary infection due to the presence of exogenous IL-25. These facts indicate that resistance is exclusively mediated by IL-25 independently of

the presence of IL-13 and STAT6 activation, probably in relation to M2 activation. Blocking of the IL-13 receptors took the values of iNOS expression to almost zero, together with overexpression of Arg1 indicating an increased M2 activation. It is well known that IL-25 induces alternative activation of macrophages and this an important mechanism for parasite rejection [8,41]. Independently of the presence of IL-13, M2 has been shown to be crucial for immunity against several intestinal helminths, such as *H. polygyrus* [42]. An interesting feature is the upregulation of IL-13 after blocking of its receptors. Smith et al. [8] obtained similar results in rIL-25-treated mice in *H. polygyrus* infections, reporting that M2 may represent a major source of IL-13 and these authors demonstrated that IL-4, in addition with IL-4Ra signaling, is required for M2 activation and parasite elimination. Expression of IL-25R in M2 could be required for the parasite expulsion in the presence of IL-4Ra signaling [8]. Our results support that M2 activation and the subsequent IL-13 overexpression do not depend on type I receptor signaling. Although the IL-4 expression was not very high, this cytokine may well acts via type I receptor signaling enhancing the resistance to *E. caproni*. Strikingly, treatment of mice with rIL-4 did not yield neither resistance nor M2 activation, probably in relation to the lack of IL-25 production. This suggest that IL-4, but not IL-13, might be necessary for resistance along with IL-25.

A striking feature of *E. caproni* infections in mice is that tuft cell hyperplasia and the subsequent IL-25 overexpression exclusively occurs as a consequence of the healing of the infection. Howitt and co-workers [14] suggested that IL-25 upregulation in intestinal helminth infection is initiated during colonization by the recognition of parasite compounds by tuft cells via taste chemosensory pathways. To this purpose, tuft cells possess multiple taste-chemosensory G protein coupled receptors and many of them require the G protein subunit gustducin and the transient receptor potential cation channel subfamily M member 5 (TRMP5) to transduce the signals [43] Howitt et al. [14] reported that disruption of chemosensory signaling by the loss of TRMP5 abrogated the tuft cell expansion and IL-25 upregulation on mice infected with *N. brasiliensis*, *T. spiralis*, or *H. polygyrus*. Although other mechanisms of immune suppression cannot be discarded [44], the lack of IL-25 expression in both *E. caproni* primary and challenge infections suggests that parasite components do not activate taste chemosensory pathways in tuft cells of mice which explain the susceptibility to both type of infections. The fact that expansion of GATA3+ cells exclusively occurs after a secondary infection in presence of IL-25, may indicate that only the simultaneous combination of signals provided by the parasite and IL-25 are able to induce the polarization to Th2.

Conclusions

Susceptibility of mice relies in the inability of mice to produce IL-25 in response to infection. In contrast to primary infection, secondary infection elicits a type 2 response, even in the absence of IL-25 expression. Despite the development of a type 2 response, mice are susceptible to secondary infection in relation to the lack of IL-25. Resistance to infection is due to IL-25, which acts autonomously from Th2 response in the parasite clearance. These results may be of importance for the understanding of mechanisms inducing resistance to infections both in humans and animals.

Abbreviations

wpi: weeks post-infection; wppi: weeks post-primary infection; wpsi: weeks post-secondary infection; wppt: weeks post-treatment with praziquantel; pzq: praziquantel; RELM- β : resistin-like molecule beta; STAT6: signal transducer and activator of transcription 6; TSLP: thymic stromal lymphopoietin; iNOS: inducible nitric oxide synthase; Ct: cycle threshold; GATA3: GATA Binding Protein 3; DCLK1: doublecortin like kinase 1; JAK: Janus kinase; TRMP5: transient receptor potential cation channel subfamily M member 5.

Declarations

Acknowledgments

The authors are sincerely grateful to Prof. Rick M. Maizels and Dr Stephan Löser (Wellcome Centre for Integrative Parasitology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK) for the critical reading of the manuscript and the collaboration provided in some of the experiments included in this work. A part of the experiments were performed in the Wellcome Centre for Integrative Parasitology, Institute of Infection, Immunity and Inflammation of the College of Medical, Veterinary, and Life Sciences of the University of Glasgow (Glasgow, UK) by MAI in a stage financially supported by the Erasmus program of the UE and the Cámara de Comercio, Industria, Servicios y Navegación (Valencia, Spain).

Ethics approval and consent to participate

This study was approved by the Ethical Committee of Animal Welfare and Experimentation of the University of Valencia (Ref. #A18348501775). Protocols adhered to Spanish (Real Decreto 53/2013) and European (2010/63/UE) regulations.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Funding

Research at Universitat de València was supported by Ministerio de Economía y Competitividad (Madrid, Spain) (grant number: BFU2016-75639-P) and from Ministerio de Sanidad y Consumo (Madrid, Spain)

(No. RD12/0018/0013, Red de Investigación Cooperativa en Enfermedades Tropicales – RICET, IV National Program of I+D+I 2008-2011, ISCIII – Subdirección General de Redes y Centros de Investigación Cooperativa and FEDER). Research at the University of Glasgow was financially supported by the Erasmus program of the UE and the Cámara de Comercio, Industria, Servicios y Navegación (Valencia, Spain).

Authors' contributions

MAI, MPC and RT carried out the experiments. MAI and RT designed the experiments and wrote the manuscript. CMA JGE and RT analyzed the data and revised the manuscript. RT was the senior investigator for the project and was responsible for project design, statistical analysis, and writing the manuscript. All authors read and approved the final manuscript.

Author details

¹Área de Parasitología, Departamento de Farmacia y Tecnología Farmacéutica y Parasitología, Facultad de Farmacia, Universitat de València, Avda. Vicent Andrés Estellés s/n, 46100 Burjassot, Valencia, Spain.

References

1. Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. Global numbers of infection and disease burden of soil transmitted helminth infections in 2010. *Parasit Vectors*. 2014; 21: 7-37.
2. Yasuda K, Nakanishi K. Host responses to intestinal nematodes. *Int Immunol*. 2018; 30: 93-102.
3. Jasmer DP, Rosa BA, Tyagi R, Mitreva M. Omics driven understanding of the intestines of parasitic nematodes. *Front Genet*. 2019; 25: 652.
4. Hewitson JP, Maizels RM. Vaccination against helminth parasite infections. *Expert Rev Vaccines*. 2014; 13: 473- 87.
5. Grenis R.K. Immunity to helminths: resistance, regulation, and susceptibility to gastrointestinal nematodes. *Annu Rev Immunol*. 2015; 33: 201–25.
6. Cortés A, Muñoz-Antoli C, Esteban JG, Toledo R. Th2 and Th1 responses: clear and hidden sides of immunity against intestinal helminths. *Trends Parasitol*. 2017; 33: 678-93.
7. Harris NL, Loke P. Recent advances in type-2-cell-mediated immunity: insights from helminth infection. *Immunity*. 2017; 47: 1024-36..
8. Smith KA, Löser S, Varyani F, Harcus Y, McSorley HJ, McKenzie AN, et al. Concerted IL-25R and IL-4Rα signaling drive innate type 2 effector immunity for optimal helminth expulsion. *Elife*. 2018; 7: e38269.
9. Owyang AM, Zaph C, Wilson EH, Guild KJ, McClanahan T, Miller HR, et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. *J*

- Exp Med. 2006; 203: 843-9.
10. Kleinschek MA, Owyang AM, Joyce-Shaikh B, Langrish CL, Chen Y, Gorman DM, et al. IL-25 regulates Th17 function in autoimmune inflammation. *J Exp Med.* 2007; 204: 161-70.
 11. Su J, Chen T, Ji XY, Liu C, Yadav PK, Wu R, et al. IL-25 downregulates Th1/Th17 immune response in an IL-10-dependent manner in inflammatory bowel disease. *Inflamm. Bowel Dis.* 2013; 19: 720–8.
 12. Liu D, Cao T, Wang N, Liu C, Ma N, Tu R, et al. IL-25 attenuates rheumatoid arthritis through suppression of Th17 immune responses in an IL-13-dependent manner. *Sci Rep.* 2016; 6: 36002.
 13. Gerbe F, Sidot E, Smyth DJ, Ohmoto M, Matsumoto I, Dardalhon V, et al. Intestinal epithelial tuft cells initiate type 2 mucosal immunity to helminth parasites. *Nature.* 2016; 529: 226-30.
 14. Howitt MR, Lavoie S, Michaud M, Blum AM, Tran SV, Weinstock JV, et al. Tuft cells, taste-chemosensory cells, orchestrate parasite type 2 immunity in the gut. *Science.* 2016; 351: 1329-33.
 15. von Moltke J, Ji M, Liang HE, Locksley, RM. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. *Nature;* 2016; 529: 221-5.
 16. Mearns H, Forbes-Blom EE, Camberis M, Tang SC, Kyle R, Harvie M, et al. IL-25 exhibits disparate roles during Th2-cell differentiation versus effector function. *Eur J Immunol.* 2014; 44: 1976-80.
 17. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. *J Exp Med.* 2007; 204: 1837-47.
 18. Toledo R, Esteban JG An update on human echinostomiasis. *Trans R Soc Trop Med Hyg.* 2016; 110: 37-45.
 19. Toledo R, Álvarez-Izquierdo M, Muñoz-Antoli C, Esteban JG. Intestinal Trematode Infections. *Adv Exp Med Biol.* 2019; 1154: 181-213.
 20. Toledo R, Esteban JG Fried B. Recent advances in the biology of echinostomes. *Adv Parasitol.* 2009; 69: 147-204.
 21. Toledo R, Fried B. Echinostomes as experimental models for interactions between adult parasites and vertebrate hosts. *Trends Parasitol.* 2005; 21, 251-4.
 22. Toledo R, Espert A, Carpena I, Muñoz-Antoli C, Fried B, Esteban JG. The comparative development of *Echinostoma caproni* (Trematoda: Echinostomatidae) adults in experimentally infected hamsters and rats. *Parasitol Res.* 2004; 93: 439-44.
 23. Muñoz-Antoli C, Sotillo J, Monteagudo C, Fried B, Marcilla A, Toledo R. Development and pathology of *Echinostoma caproni* in experimentally infected mice. *J Parasitol.* 2007; 93: 854-9.
 24. Trelis M, Sotillo J, Monteagudo C, Fried B, Marcilla A, Esteban JG, et al. *Echinostoma caproni* (Trematoda): differential in vivo cytokine responses in high and low compatible hosts. *Exp Parasitol.* 2011; 127: 387-97.
 25. Sotillo J, Trelis M, Cortes A, Fried B, Marcilla A, Esteban JG, Toledo R. Th17 responses in *Echinostoma caproni* infections in hosts of high and low compatibility. *Exp Parasitol.* 2011; 129: 307-11.

26. Muñoz-Antoli C, Cortés A, Santano R, Sotillo J, Esteban JG, Toledo R. Interleukin-25 induces resistance against intestinal trematodes. *Sci Rep*. 2016b; 6: 34142.
27. Muñoz-Antoli C, Cortés A, Martín-Grau C, Fried B, Esteban JG, Toledo R. Partial resistance to homologous challenge infections of the digenean *Echinostoma caproni* in ICR mice. *J Helminthol*. 2016a; 140: 37-47.
28. Cortés A, Sotillo J, Muñoz-Antoli C, Martín-Grau C, Esteban JG, Toledo R, et al. Resistance against *Echinostoma caproni* (Trematoda) secondary infections in mice is not dependent on the ileal protein production. *J Proteomics*. 2016; 140: 37-47.
29. Cortés A, Muñoz-Antoli C, Martín-Grau C, Esteban JG, Grecis RK, Toledo R, et al. Differential alterations in the small intestine epithelial cell turnover during acute and chronic infection with *Echinostoma caproni* (Trematoda). *Parasit Vectors*. 2015a; 8: 334.
30. Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. *J Exp Med*. 2006; 203:1105-16.
31. Zhao A, Urban JF Jr, Sun R, Stiltz J, Morimoto M, Notari L, et al. Critical role of IL-25 in nematode infection induced alterations in intestinal function. *J Immunol*. 2010; 185: 6921–9.
32. Angkasekwinai P, Srimanote P, Wang YH, Pootong A, Sakolvaree Y, Pattanapanyasat K, et al. Interleukin-25 (IL-25) promotes efficient protective immunity against *Trichinella spiralis* infection by enhancing the antigen-specific IL-9 response. *Infect Immun*. 2013; 81: 3731-41.
33. Angkasekwinai P, Sodthawon W, Jeerawattanawart S, Hansakon A, Pattanapanyasat K, Wang YH. ILC2s activated by IL-25 promote antigen-specific Th2 and Th9 functions that contribute to the control of *Trichinella spiralis* infection. *PLoS One*. 2017; 12: e0184684.
34. Burrows K, Ngai L, Wong F, Won D, Mortha A. ILC2 activation by protozoan commensal microbes. *Int J Mol Sci*. 2019; 20: e4865.
35. Pei C, Zhao C, Wang AJ, Fan AX, Grinchuk V, Smith A, et al. Critical role for interleukin-25 in host protective Th2 memory response against *Heligmosomoides polygyrus bakeri*. *Infect Immun*. 2016; 84: 3328-37.
36. Andrews AL, Holloway JW, Holgate ST, Davies DE. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. *J Immunol*. 2006; 176: 7456-61.
37. McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. *Cytokine*. 2015; 75: 38-50. doi: 10.1016/j.cyto.2015.05.023. PMID: 26187331.
38. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. *Allergy*. 2020;75: 54-62.
39. Giuffrida P, Caprioli F, Facciotti F, Di Sabatino A. The role of interleukin-13 in chronic inflammatory intestinal disorders. *Autoimmun Rev*. 2019; 18: 549-55.
40. Rahaman SO, Sharma P, Harbor PC, Aman MJ, Vogelbaum MA, Haque SJ. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells.

Cancer Res. 2002; 62: 1103-9.

41. Li Q, Ma L, Shen S, Guo Y, Cao Q, Cai X, et al. Intestinal dysbacteriosis-induced IL-25 promotes development of HCC via alternative activation of macrophages in tumor microenvironment. J Exp Clin Cancer Res. 2019; 38: 303.
42. Anthony RM, Urban JF Jr, Alem F, Hamed HA, Rozo CT, Boucher JL, et al. (2006) Memory T(H)2 cells induce alternatively activated macrophages to mediate protection against nematode parasites. Nat. Med. 2006; 12: 955-60.
43. Huang Y, Guo L, Qiu J, Chen X, Hu-Li J, Siebenlist U, et al. IL-25-responsive, lineage-negative KLRG1(hi) cells are multipotential 'inflammatory' type 2 innate lymphoid cells. Nat. Immunol. 2015; 16, 161-9.
44. Valanparambil RM, Tam M, Jardim A, Geary TG, Stevenson MM. Primary *Heligmosomoides polygyrus bakeri* infection induces myeloid-derived suppressor cells that suppress CD4(+) Th2 responses and promote chronic infection. Mucosal Immunol. 2017; 10: 238-49.

Figures




Figure 1

Blocking of IL-25 in challenge infections with *Echinostoma caproni* reverts resistance to infection despite the development of a Th2 response. (A) worm recovery in mIL-25-treated ICR mice and non-treated mice after a challenge infection with *E. caproni*; (B) expression of cytokine mRNA in the intestinal tissue of mIL-25-treated ICR mice and non-treated mice after a challenge infection with *E. caproni*. The relative quantities (RQ) of cytokine genes are shown after normalization with β -actin and standardization of the

relative amount against day 0 sample. Vertical bars represent the standard deviation. *: significant differences with respect to non- m α -IL-25-treated mice. a: significant differences with respect to naïve mice controls; b: significant differences between groups (p<0.05).




Figure 2

Blocking of IL-25 induced alternative activation of macrophages after challenge infection. (A) Pattern of macrophage activation is different in primary and secondary infections analyzed by the gene expression of markers mRNA of both classical (Arg II and iNOS) and alternative (Arg I and Ym-1) activation of macrophages in the intestinal tissue of m α -IL-25-treated mice and non-treated mice after a challenge infection with *E. caproni*; (B) expression of RELM- β mRNA in the intestinal tissue of m α -IL-25-treated ICR mice and non-treated mice after a challenge infection with *E. caproni*. The relative quantities (RQ) of cytokine genes are shown after normalization with β -actin and standardization of the relative amount against day 0 sample. Vertical bars represent the standard deviation. a: significant differences with respect to naïve mice controls; b: significant differences between groups (p<0.05).




Figure 3

IL-25 gene expression returned to baseline levels 10 weeks after pharmacological cure of a primary infection. Expression of IL-25 mRNA in the intestinal tissue mice after curation with praziquantel of a primary infection with *E. caproni*. The relative quantities (RQ) of cytokine genes are shown after normalization with β -actin and standardization of the relative amount against day 0 sample. Vertical bars represent the standard deviation.




Figure 4

Recovering of baseline expression of IL-25 mRNA after healing of the primary infection reverted the resistance against challenge infection together with a Th2 response. (A) worm recovery of a primary infection in naïve mice and in that of a challenge infection in mice in which the basal levels of mRNA expression were recovered after the cure of a primary infection; (B) expression of cytokine mRNA in the intestinal tissue of of both groups of mice at 2 weeks after primary and secondary infection, respectively. The relative quantities (RQ) of cytokine genes are shown after normalization with β -actin and standardization of the relative amount against day 0 sample. Vertical bars represent the standard deviation. a: significant differences with respect to naïve mice controls; b: significant differences between groups ($p < 0.05$).




Figure 5

Treatment of mice with either mIL-4R or rIL-13R2 abrogates Th2 response and alters the pattern of macrophage activation despite the presence of IL-25. (A) Expression of cytokine mRNA in the intestinal tissue IL-25-treated-mice that were also treated with mIL-4R or rIL-13R2 at 2 weeks post-primary infection with *Echinostoma caproni*; (B) Pattern of macrophage activation analyzed by the expression of markers mRNA of both classical (Arg II and iNOS) and alternative (Arg I and Ym-1) activation of macrophages in the intestinal tissue of IL-25-treated-mice that were also treated with mIL-4R or rIL-13R2 at 2 weeks post-primary infection with *Echinostoma caproni*. The relative quantities (RQ) of cytokine genes are shown after normalization with β -actin and standardization of the relative amount against day 0 sample. Vertical bars represent the standard deviation. a: significant differences with respect to naïve mice controls; b: significant differences between groups ($p < 0.05$).




Figure 6

Pharmacological curation of an *Echinostoma caproni* primary infection exacerbates the expression of IL-13R α 2. (A) schematic representation of the experimental protocol; (B) Levels of mRNA expression of IL-13R α 2 in the intestinal tissue of mice primarily infected at 4 weeks post infection (4wppi), at 2 weeks post-

treatment with praziquantel (2wppt) and at 2 weeks post-secondary infection (2 wpsi) The relative quantities (RQ) of cytokine genes are shown after normalization with β -actin and standardization of the relative amount against day 0 sample. Vertical bars represent the standard deviation. a: significant differences with respect to naïve mice controls; b: significant differences between groups ($p < 0.05$).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryFig1.tif](#)
- [SupplementaryFig2.tif](#)
- [SupplementaryFig3.tif](#)
- [Additionalfile1TableS1.docx](#)
- [SupplementaryFig4.tif](#)
- [Additionalfiles.docx](#)